Biomarkers in Urologic Cancer, An Issue of Urologic Clinics of North America

Kevin R. Loughlin

Description

The past decade has been marked by the acceleration of our understanding of the molecular biology of cancer. Simultaneously, there have been increasing exigencies to diagnose, treat and follow cancer patients more economically. Biomarkers represent the marriage of science and economics. Biomarkers offer the potential to increase the precision of diagnosis, prognosis, and surveillance of urological malignancies. This issue presents the cutting-edge advances of biomarker technology to urologic oncology.

Sujets

• Médecine
• Médecine Générale
• Medical
• Urology

Informations

• Publié par: Elsevier
• Date de parution: 19 janvier 2016
• Nombre de lectures: 0
• EAN13: 9780323417198
• Langue: English
• Poids de l'ouvrage: 3 Mo

Extrait

Biomarkers in Urologic Cancer
Urologic Clinics of North America
Editor
Kevin R. Loughlin, MD, MBA
Division of Urology, Harvard Medical School, Brigham Women s Hospital, Boston, MA, USA
Consulting Editor
Samir S. Taneja

Clinics Review Articles

www.urologic.theclinics.com

February 2016 Volume 43 Number 1
Table of Contents
Cover image
Title page
Copyright
CME Accreditation Page
Contributors
Consulting Editor
Editor
Authors
Forthcoming Issues
Forthcoming Issues
Recent Issues
Foreword. Biomarkers in Urologic Cancer
Preface. Biomarkers in Urologic Cancer
The Prostate Health Index: Its Utility in Prostate Cancer Detection
Key points
Introduction
Phi as a predictor of biopsy outcome
Phi as a component of multivariable risk stratification
Phi as a predictor of treatment outcome
Comparison of phi with other prostate cancer tests
Summary
References
New Genetic Markers for Prostate Cancer
Key points
Introduction
Principles of design and evaluation
Tests before diagnosis
Urinary-based gene expression assays
Tissue-based gene expression tests
Prolaris (Myriad Genetics Inc, Salt Lake City, Utah)
Decipher (GenomeDX, Vancouver, British Columbia)
Summary
References
Urinary Biomarkers for Prostate Cancer
Key points
Introduction
RNA-based markers
DNA-based markers
Protein-based markers
Other urinary markers
Summary
References
4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening
Key points
Introduction
Limitations in prostate-specific antigen-based screening for prostate cancer
Human kallikreins
Kallikrein panel
Four kallikrein studies in men before biopsy
Four kallikrein studies in men with prior negative biopsy
Surgical pathology prediction
Development of the 4K probability score
The economic impact of the 4 kallikrein panel and 4Kscore
Summary
References
Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer
Key points
Introduction
Material and method
Commercially available biomarkers
Investigational biomarkers
Summary
References
Emerging Bladder Cancer Biomarkers and Targets of Therapy
Key points
Genetic and molecular biomarkers
Genomics of bladder cancer
Biomarkers and pathway targets
Monitoring/detection methods
Clinical trials
References
Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer
Key points
Introduction and aims
The clinical need and promise of predictive biomarkers
Emerging opportunities for personalized therapeutic regimens
Individual biomarkers of response
New approaches to the classification of bladder cancer
Clinical trials using molecularly guided therapy selection
Acknowledgments
References
Diagnostic Biomarkers in Eosinophilic Renal Neoplasms
Key points
Introduction
Discussion
Summary
References
Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma
Key points
Introduction
Circulating/blood-based biomarkers
Tissue-based biomarkers
Single-nucleotide polymorphism as biomarkers for response
Future directions
Summary
References
Prognostic Role of Cell Cycle and Proliferative Markers in Clear Cell Renal Cell Carcinoma
Key points
Introduction
Cell cycle and cell proliferation
Prognostic value of cell cycle and proliferative markers
Marker combinations
Summary
References
Current Clinical Applications of Testicular Cancer Biomarkers
Key points
Introduction
Clinical utility of traditional serum tumor markers
Available biomarkers for testicular cancer
Future biomarkers for testicular cancer under investigation
References
MicroRNAs in Testicular Cancer Diagnosis and Prognosis
Key points
Introduction
Molecular aspects of microRNA biogenesis
MicroRNAs in testicular cancer
MicroRNAs as diagnostic biomarkers in testicular cancer
MicroRNAs, prognosis, and cisplatin-based treatment
References
The Emerging Role and Promise of Biomarkers in Penile Cancer
Key points
Introduction
Plasmatic biomarkers
Proliferation associated biomarkers
Human papillomavirus
p53
Cytogenetic markers
Summary/discussion
References
Index
Copyright
ELSEVIER
1600 John F. Kennedy Boulevard Suite 1800 Philadelphia, Pennsylvania, 19103-2899
http://www.theclinics.com
UROLOGIC CLINICS OF NORTH AMERICA Volume 43, Number 1 February 2016 ISSN 0094-0143, ISBN-13: 978-0-323-41718-1
Editor: Kerry Holland
Developmental Editor: Alison Swety
2016 Elsevier Inc. All rights reserved.
This periodical and the individual contributions contained in it are protected under copyright by Elsevier, and the following terms and conditions apply to their use:
Photocopying
Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. For information on how to seek permission visit www.elsevier.com/permissions or call: ([phone] (UK)/([phone] (USA).
Derivative Works
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations (please consult www.elsevier.com/permissions ).
Electronic Storage or Usage
Permission of the Publisher is required to store or use electronically any material contained in this periodical, including any article or part of an article (please consult www.elsevier.com/permissions ). Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.
Notice
No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.
Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Urologic Clinics of North America (ISSN 0094-0143) is published quarterly by Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710. Months of issue are February, May, August, and November. Business and Editorial Offices: 1600 John F. Kennedy Blvd., Suite 1800, Philadelphia, PA 19103-2899. Periodicals postage paid at New York, NY and additional mailing offices. Subscription prices are $360.00 per year (US individuals), $660.00 per year (US institutions), $415.00 per year (Canadian individuals), $825.00 per year (Canadian institutions), $515.00 per year (foreign individuals), and $825.00 per year (foreign institutions). Foreign air speed delivery is included in all Clinics subscription prices. All prices are subject to change without notice. POSTMASTER: Send address changes to Urologic Clinics of North America , Elsevier Health Sciences Division, Subscription Customer Service, 3251 Riverport Lane, Maryland Heights, MO 63043. Customer Service: 1-800-654-2452 (US). From outside the United States, call 1-314-447-8871. Fax: [phone]. E-mail: [e-mail] (for print support) and [e-mail] (for online support) .
Reprints . For copies of 100 or more, of articles in this publication, please contact the Commercial Reprints Department, Elsevier Inc., 360 Park Avenue South, New York, New York 10010-1710. Tel.: [phone]; Fax: [phone]; E-mail: [e-mail] .
Urologic Clinics of North America is covered in MEDLINE/PubMed ( Index Medicus ), Excerpta Medica, Current Contents/Clinical Medicine, Science Citation Index, and ISI/BIOMED .
Printed in the United States of America.
CME Accreditation Page
Program Objective
The goal of Urologic Clinics of North America is to keep practicing urologists and urology residents up to date with current clinical practice in urology by providing timely articles reviewing the state of the art in patient care.
Target Audience
Practicing urologists, urology residents and other health care professionals practicing in the discipline of urology.
Learning Objectives
Upon completion of this activity, participants will be able to:

1. Review the use of the Prostate Health Index and new genetic markers in diagnosing prostate cancer.
2. Discuss the current use of biomarkers for detection and targeted therapy of bladder cancer.
3. Recognize the diagnostic and prognostic roles of biomarkers in renal neoplasms and renal cell carcinomas.
Accreditation
The Elsevier Office of Continuing Medical Education (EOCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The EOCME designates this enduring material for a maximum of 15 AMA PRA Category 1 Credit (s) . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other health care professionals requesting continuing education credit for this enduring material will be issued a